BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38361420)

  • 1. A novel ABCG2 variant causing Jr(a-) phenotype.
    Kwon SS; Yun YE; Kim NH; Suh EJ; Kim SK; Kim S
    Transfusion; 2024 Apr; 64(4):E9-E10. PubMed ID: 38361420
    [No Abstract]   [Full Text] [Related]  

  • 2. ABCG2 null alleles define the Jr(a-) blood group phenotype.
    Zelinski T; Coghlan G; Liu XQ; Reid ME
    Nat Genet; 2012 Jan; 44(2):131-2. PubMed ID: 22246507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on the JR blood group system.
    Castilho L
    Immunohematology; 2019 Jun; 35(2):43-44. PubMed ID: 31246485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular analysis of immunized Jr(a-) or Lan- patients and validation of a high-throughput genotyping assay to screen blood donors for Jr(a-) and Lan- phenotypes.
    Haer-Wigman L; Ait Soussan A; Ligthart P; de Haas M; van der Schoot CE
    Transfusion; 2014 Jul; 54(7):1836-46. PubMed ID: 24456066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical characterization of Jr(a-) blood type-related ABCG2 variants: Arg147Trp and Ser572Arg disrupt the plasma membrane localization of ABCG2.
    Toyoda Y; Matsuo H; Tanaka M; Stiburkova B; Takada T
    Transfusion; 2024 Feb; 64(2):412-414. PubMed ID: 38379528
    [No Abstract]   [Full Text] [Related]  

  • 6. Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior.
    Saison C; Helias V; Ballif BA; Peyrard T; Puy H; Miyazaki T; Perrot S; Vayssier-Taussat M; Waldner M; Le Pennec PY; Cartron JP; Arnaud L
    Nat Genet; 2012 Jan; 44(2):174-7. PubMed ID: 22246505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new ABCG2 null allele with a 27-kb deletion including the promoter region causing the Jr(a-) phenotype.
    Ogasawara K; Osabe T; Suzuki Y; Tsuneyama H; Isa K; Kawai M; Obara K; Ogiyama Y; Ito S; Uchikawa M; Satake M; Tadokoro K
    Transfusion; 2015 Jun; 55(6 Pt 2):1467-71. PubMed ID: 25522810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two novel ABCG2 alleles resulting in a Jr(a-) phenotype.
    Berardi P; Cote J; Vege S; Aeschlimann J; Cserti-Gazdewich C; Westhoff CM
    Transfusion; 2017 Nov; 57(11):2811-2812. PubMed ID: 28836283
    [No Abstract]   [Full Text] [Related]  

  • 9. Genotyping of the ABCG2 gene using Matrix-Associated Laser Desorption/Ionisation, Time-of-Flight Mass Spectrometry.
    Tanaka M; Kamada I; Takahashi J; Kimura T; Tani Y
    Transfus Med; 2018 Jun; 28(3):255-260. PubMed ID: 28940904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The JR blood group system: identification of alleles that alter expression.
    Hue-Roye K; Zelinski T; Cobaugh A; Lomas-Francis C; Miyazaki T; Tani Y; Westhoff CM; Reid ME
    Transfusion; 2013 Nov; 53(11):2710-4. PubMed ID: 23438071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new genetic background for the Jr(a-) blood group phenotype caused by the ABCG2*439T allele encoding a p.Arg147Trp change.
    Wieckhusen C; Rink G; Scharberg EA; Rothenberger S; Stürtzel A; Richter E; Bugert P
    Transfusion; 2017 Dec; 57(12):3063-3064. PubMed ID: 29106709
    [No Abstract]   [Full Text] [Related]  

  • 12. A review of the JR blood group system.
    Castilho L; Reid ME
    Immunohematology; 2013; 29(2):63-8. PubMed ID: 24094238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The JR blood group system (ISBT 032): molecular characterization of three new null alleles.
    Hue-Roye K; Lomas-Francis C; Coghlan G; Zelinski T; Reid ME
    Transfusion; 2013 Jul; 53(7):1575-9. PubMed ID: 23066723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletion of Exons 3 through 5 of ABCG2 causes the Jr(a-) phenotype in a West African woman.
    Saison C; Cartron JP; Arnaud L
    Transfusion; 2015 Nov; 55(11):2766-7. PubMed ID: 26173500
    [No Abstract]   [Full Text] [Related]  

  • 15. Defining the Jr(a-) phenotype in the Japanese population.
    Tanaka M; Kamada I; Takahashi J; Kimura K; Matsukura H; Tani Y
    Transfusion; 2014 Feb; 54(2):412-7. PubMed ID: 23713577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Analysis of
    Słomka M; Sobalska-Kwapis M; Korycka-Machała M; Dziadek J; Bartosz G; Strapagiel D
    Genes (Basel); 2020 Sep; 11(10):. PubMed ID: 33003314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional non-synonymous variants of ABCG2 and gout risk.
    Stiburkova B; Pavelcova K; Zavada J; Petru L; Simek P; Cepek P; Pavlikova M; Matsuo H; Merriman TR; Pavelka K
    Rheumatology (Oxford); 2017 Nov; 56(11):1982-1992. PubMed ID: 28968913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2.
    Toyoda Y; Pavelcová K; Klein M; Suzuki H; Takada T; Stiburkova B
    Arthritis Res Ther; 2019 Oct; 21(1):219. PubMed ID: 31661014
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacogenomics with red cells: a model to study protein variants of drug transporter genes.
    Flegel WA; Srivastava K; Sissung TM; Goldspiel BR; Figg WD
    Vox Sang; 2021 Feb; 116(2):141-154. PubMed ID: 32996603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.
    Merćep I; Radman I; Trkulja V; Božina T; Šimičević L; Budimir E; Ganoci L; Božina N
    Eur J Clin Pharmacol; 2022 Feb; 78(2):227-236. PubMed ID: 34668025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.